SAN FRANCISCO — The addition of pembrolizumab to docetaxel failed to significantly extend survival for men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to results of the randomized phase 3 KEYNOTE-921 trial.
Results showed slight numerical improvements in radiographic PFS and OS — the study’s key endpoints — with the experimental regimen, but neither difference reached statistical significance, findings presented at ASCO Genitourinary Cancers Symposium showed.
“It’s disappointing, but I’m glad that the hypothesis